👀@OndoFinance just dropped new assets. All 264 routing through 1inch Swap API via our partners.Ready to build? Ship faster with AI-native integration → https://t.co/b0wn2I54voOndo Finance (@OndoFinance):New tokenized stocks just landed onchain.The largest tokenized stock platform by TVL just got bigger, with 60+ new assets spanning key sectors and trends:✅ AI✅ Oil✅ Data✅ Space✅ Biotech✅ Defense✅ Quantum✅ China exposure✅ & many moreOndo Global Markets now https://t.co/xFFmCgOTkL ...

On February 17, 2026, 5AM Venture Management reported selling its entire stake in Praxis Precision Medicines (NASDAQ:PRAX), an estimated $9.01 million trade based on last-disclosed position values. What happened According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, 5AM Venture Management sold its 170,000 shares of Praxis Precision Medicines. The fund now reports no position in PRAX, and the total quarter-end valuation for this holding was reduced by $9.01 million as a re ...

Core Viewpoint - Amneal Pharmaceuticals, Inc. (AMRX) has shown positive stock performance since receiving a Buy rating a year ago, indicating a successful investment call [1]. Group 1: Company Overview - Amneal Pharmaceuticals, Inc. is highlighted as a stock that has performed well, with a significant increase in value since the last analysis [1]. Group 2: Analyst Background - The analysis is conducted by a biotech consultant with over 5 years of experience in the biotech, healthcare, and pharma sectors, having prepared detailed reports on more than 1,000 companies [1]. - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts, buy and sell ratings, product sales forecasts, and financial analyses [1].

Summary of Key Points from the Investor Presentation on China Equity Strategy Industry Overview - The presentation focuses on the **China equity market** and its performance amid global volatility, particularly in relation to the **MSCI China index** and its comparison with other emerging markets [6][10]. Core Insights and Arguments - **Performance Metrics**: The MSCI China index has underperformed compared to other emerging markets year-to-date (YTD) due to the AI memory super-cycle, but has shown resilience amid geopolitical uncertainties, particularly related to oil prices [6][10]. - **Earnings Growth**: Earnings estimates for MSCI China have been raised by 1.2 percentage points for 2026 and 1.8 percentage points for 2027, indicating a positive outlook driven by a few key stocks [42][39]. - **Regulatory Environment**: A shift from regulatory rectification to revitalization is noted, which is expected to be more supportive of the private sector [27]. - **Geopolitical Factors**: An interim truce in US-China trade negotiations has alleviated some investor concerns regarding decoupling, contributing to a more stable investment environment [27]. - **Economic Policy**: The Chinese government has maintained a supply-centric policy with a focus on economic rebalancing at a calibrated pace, as reflected in the recent National People's Congress (NPC) fiscal package [53][54]. Additional Important Insights - **Market Volatility**: High volatility is expected to persist globally as the world enters a multipolar era, with geopolitical uncertainties influencing market dynamics [27]. - **Sector Performance**: The earnings growth forecast for various sectors within MSCI China shows significant variation, with consumer discretionary and technology sectors expected to lead in growth [51]. - **Property Market Weakness**: The property market remains weak, with ongoing deleveraging and a significant decline in housing investment, indicating a challenging environment for real estate [58][62]. - **Corporate Earnings Quality**: There is a focus on the quality and sustainability of corporate earnings, which is crucial for long-term investment strategies [27]. Conclusion - The presentation outlines a cautiously optimistic outlook for the China equity market, emphasizing the importance of regulatory support, geopolitical stability, and sector-specific growth opportunities. The overall sentiment suggests that while challenges remain, particularly in the property sector, there are positive indicators for earnings growth and market resilience moving forward [27][39][53].

Core Insights - The article emphasizes the importance of understanding investment strategies, asset allocation, and market conditions globally, particularly in the USA [1] Investment Strategy - The investment philosophy focuses on finding Growth at a Reasonable Price (GARP), inspired by investor Peter Lynch, which seeks businesses with strong earnings growth at reasonable valuations [1] - The analysis is grounded in fundamental analysis, aiming to identify companies with the potential for continued growth [1] Sector Focus - Key sectors of interest include Financials, Aerospace/Defense, and Software, along with growth sectors such as Technology (AI, Cybersecurity, Cloud, Fintech), Healthcare (Biotech, Digital Health), Energy Transition (Renewables, EVs, Green Manufacturing), and Advanced Industries (Robotics, Space, Advanced Manufacturing, Future Mobility) [1] - These sectors are driven by trends like digital disruption, sustainability, and evolving demographics [1] Global Market Insights - The article reflects on the author's extensive experience at Morgan Stanley, engaging with various global trading desks, which has fostered a deep interest in global market trends and their impact on investments [1] - The insights aim to inspire individuals to develop an interest in investing and to understand the complexities of the rapidly changing world [1]

Summary of Key Points from the Conference Call Industry Overview - **Industry**: Economic Policy and Growth Forecasts in China and Hong Kong - **Company**: Morgan Stanley Asia Limited Core Insights and Arguments - **2026 GDP Target**: Remains unchanged at approximately 5%, aimed at anchoring market confidence during the first year of the 15th Five-Year Plan (FYP) [3] - **Policy Stance**: Focus on cushioning rather than lifting economic activity, with a flat initial envelope of 11.6% of GDP for 2026, including a 4% official deficit [3] - **Fiscal Policy**: A modest fiscal package of RMB 500-600 billion is expected, which includes: - RMB 250-300 billion for consumer goods trade-in - RMB 100 billion for fertility support - RMB 60-120 billion for pre-school education support - RMB 100 billion increase in social welfare support [3] - **Housing Policy**: Introduction of a modest pilot program for mortgage subsidies in select cities post-NPC [3] - **Sector-Specific Focus**: Emphasis on technology localization, infrastructure, and a shift towards targeted R&D in sectors like AI, semiconductors, green energy, and biotech [3] Additional Important Content - **PPI Trends**: Recent uptick in Producer Price Index (PPI) driven by upstream sectors, indicating sluggish consumer demand [6] - **RMB Exchange Rate**: The RMB has appreciated against the USD but remains stable against a trade-weighted basket, with managed volatility by the People's Bank of China (PBoC) [11][15] - **Hong Kong GDP Growth**: Forecasts for Hong Kong's GDP growth have been raised to above-trend levels for 2026-27, driven by a property-led upswing, with residential prices expected to rise by 10% in 2026 [21][22] - **Fiscal Balance**: Consolidated fiscal balance for FY2026/27 projected at 0.6% of GDP, up from 0.1% in FY2025/26, indicating a positive fiscal outlook [25] - **Retail Market Challenges**: Hong Kong's unemployment rate has reached its highest level since 2010, driven by weaknesses in the domestic retail sector and emerging AI disruptions [29] This summary encapsulates the key points discussed in the conference call, highlighting the economic outlook and policy directions for China and Hong Kong, along with potential investment opportunities and risks.

Core Insights - The article emphasizes the importance of understanding investment strategies, asset allocation, and market conditions globally, particularly in the USA [1] Investment Strategy - The investment philosophy focuses on finding Growth at a Reasonable Price (GARP), inspired by investor Peter Lynch, which seeks businesses with strong earnings growth at reasonable valuations [1] - The analysis is rooted in fundamental analysis, aiming to identify companies with the potential for continued growth [1] Sector Focus - Key sectors of interest include Financials, Aerospace/Defense, and Software, along with growth sectors such as Technology (AI, Cybersecurity, Cloud, Fintech), Healthcare (Biotech, Digital Health), Energy Transition (Renewables, EVs, Green Manufacturing), and Advanced Industries (Robotics, Space, Advanced Manufacturing, Future Mobility) [1] - These sectors are driven by trends like digital disruption, sustainability, and evolving demographics [1] Global Market Insights - The article reflects on the author's extensive experience at Morgan Stanley, engaging with various global trading desks, which has fostered a deep interest in global market trends and their impact on investments [1] - The insights aim to inspire individuals to develop a passion for investing and to understand the complexities of the rapidly changing world [1]

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights such as buy and sell ratings, product sales forecasts for major pharmaceutical companies, integrated financial statements, discounted cash flow analysis, and market-specific analyses [1]

Core Insights - Redmile Group increased its stake in Scholar Rock Holding Corporation by purchasing 1,316,390 shares, valued at approximately $49.37 million based on quarterly average pricing [1][2] - The quarter-end value of Redmile's position in Scholar Rock increased by $84.58 million, reflecting both the acquisition of additional shares and market price movements [2] Company Overview - Scholar Rock Holding Corporation is a clinical-stage biotechnology company focused on developing therapies that modulate protein growth factor signaling, addressing unmet medical needs in neuromuscular, oncological, and fibrotic indications [6] - The company has a proprietary platform and is positioned to capitalize on innovative science in high-impact therapeutic areas through strategic collaborations and a focused pipeline [6] Financial Metrics - As of February 17, 2026, Scholar Rock's stock price was $46.45, with a market capitalization of $4.78 billion [4] - The company reported a net income of -$353.43 million (TTM) and a one-year price change of 25.71% [4] Investment Implications - The purchase by Redmile Group indicates a strong commitment to Scholar Rock, which now represents approximately 17% of the fund's assets under management [7][10] - Scholar Rock is expected to submit a Biologics License Application for apitegromab in spinal muscular atrophy, with a potential U.S. launch anticipated following approval this year [9] - The company had approximately $365 million in cash as of December 31, providing a runway into 2027 and reducing near-term dilution risk for investors [9] Market Performance - Scholar Rock's shares have increased by about 26% over the past year, outperforming the broader market and indicating that investors are recognizing the value of regulatory progress and pipeline depth [11] - The company is also developing additional programs, including FSHD and the SRK-439 myostatin inhibitor, which expand its potential market opportunities [11]

For five years biotech startups have been betting that psychedelic substances could be turned into real medicines. One of them may have hit the jackpot https://t.co/jYQeXuKKev ...